Feasibility Study for ARV manufacturing in Cameroon / Kenya


  • SOLICITATION NUMBER: 0002000149
  • INSTITUTION:  IFC
  • ASSIGNMENT LOCATION: Republic of Cameroon, Republic of Kenya
  • ISSUE DATE AND TIME: Mar 13,2023 04:00
  • CLOSING DATE AND TIME: Mar 21,2023 03:59

IFC partnered with a leading international pharmaceutical company engaged in the development, manufacturing and supply of Anti-Retroviral (“ARV”) drugs to identify and develop local manufacturing opportunities of their products in selected African countries in partnership with local manufacturers.  IFC wishes to engage a consultant/consulting firm (the “Consultant”) to complete the feasibility of a proposed API and finished drugs manufacturing facility to assist in selecting the optimal location between Cameroon and Kenya, which assessment will include an evaluation of the market, regulatory, technical and financial implementation aspects in each country respectively.

The WBG reserves the right to publicly disclose contract award information, including but not limited to, name of company receiving the award, brief description of services, and contract award amount, for any contract award valued over US$250,000. Offeror's proposal and contractual documents will remain confidential and therefore not subject to disclosure.

The World Bank reserves the right to reject any or all responses without recourse.

Welcome